Views: 1,402 | Downloads:
286
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Monitoring of Effectiveness and Safety of Generic Formulation of Meropenem for Treatment of Infections at Siriraj Hospital
Angkasekwinai N 
,
Werarak P ,
Chaiyasoot K ,
Thamlikitkul V
,
Werarak P ,
Chaiyasoot K ,
Thamlikitkul V Objective: In Siriraj Hospital, generic meropenem (Monem®) has been available and was substituted for original meropenem,
but the effectiveness and safety of using generic meropenem in a clinical setting are the main concern.
Material and Method: From July 2007 to June 2009, hospitalized patients aged 18 or older who received meropenem for 48
hours were identified from the pharmacy database of Siriraj hospital. A retrospective study was conducted. Three hundred
patients in each of original and generic meropenem groups were required to demonstrate non-inferiority of generic to original
meropenem.
Results: The mean age of all patients was 63 years. Most of the patients had co-morbidities. Approximately 90% of the
infections were health-care associated. Drug-resistant gram-negative bacteria including ESBL producing E. coli and K.
pneumoniae, P. aeruginosa and A. baumannii account for nearly 50% of all organisms. No significant difference was found
regarding characteristics, type or site of infection and pathogen between generic and original groups but for more patients in
the original group having cardiovascular disease and more patients in the generic group receiving immunosuppressive
agents. Eighty-two to 85% received meropenem with one of appropriate indications. No statistically significant difference
occurred either in an overall favorable outcome (63% vs.70.4%, p=0.07) or in overall mortality (38% vs. 32%, p=0.17), as
well as adverse effects between the original and the generic groups.
Conclusion: Generic meropenem (Monem®) was not inferior to original meropenem for therapy of infections in the hospitalized
patients at Siriraj Hospital.
Keyword: Meropenem, Effectiveness, Safety, Generic formulation
but the effectiveness and safety of using generic meropenem in a clinical setting are the main concern.
Material and Method: From July 2007 to June 2009, hospitalized patients aged 18 or older who received meropenem for 48
hours were identified from the pharmacy database of Siriraj hospital. A retrospective study was conducted. Three hundred
patients in each of original and generic meropenem groups were required to demonstrate non-inferiority of generic to original
meropenem.
Results: The mean age of all patients was 63 years. Most of the patients had co-morbidities. Approximately 90% of the
infections were health-care associated. Drug-resistant gram-negative bacteria including ESBL producing E. coli and K.
pneumoniae, P. aeruginosa and A. baumannii account for nearly 50% of all organisms. No significant difference was found
regarding characteristics, type or site of infection and pathogen between generic and original groups but for more patients in
the original group having cardiovascular disease and more patients in the generic group receiving immunosuppressive
agents. Eighty-two to 85% received meropenem with one of appropriate indications. No statistically significant difference
occurred either in an overall favorable outcome (63% vs.70.4%, p=0.07) or in overall mortality (38% vs. 32%, p=0.17), as
well as adverse effects between the original and the generic groups.
Conclusion: Generic meropenem (Monem®) was not inferior to original meropenem for therapy of infections in the hospitalized
patients at Siriraj Hospital.
Keyword: Meropenem, Effectiveness, Safety, Generic formulation
Download:
PDF